tirzepatide vs semaglutide weight loss trials versus Once Weekly in Patients with Type 2 Diabetes Summary of clinical trials that

Comparison of CT-388 (Roche/Carmot) and tirzepatide (Mounjaro/Zepbound), two dual GLP-1/GIP agonists with different signaling profiles, weight loss data, and development status.

Strong evidence supports their efficacy in inducing clinically meaningful weight loss in individuals with overweight or obesity

Green Tea Extract: Rich in antioxidants, it boosts metabolism and enhances energy

GLP-1 receptor agonist therapy, including semaglutide and tirzepatide, offers a physician-supervised path to meaningful, sustainable weight loss backed by clinical science.

12 GLP-1- , ,

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.